Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells

Cancer Research

Volumn 60, Issue 11, 2000, Pages 2936-2941

  Koshikawa, Nobuko ^a   Takenaga, Keizo ^b,c   Tagawa, Masatoshi ^a   Sakiyama, Shigeru ^c  

^a Division of Pathology   (Japan)

^b Division of Chemotherapy   (Japan)

^c CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENETICS; CANCER THERAPY; CONTROLLED STUDY; GENE THERAPY; HYPOXIC CELL; LEWIS CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SUICIDE GENE;

ANIMALS; ANOXIA; ANTIVIRAL AGENTS; BLOTTING, NORTHERN; CARCINOMA, LEWIS LUNG; CLONING, MOLECULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; LUMINESCENT PROTEINS; LYMPHOKINES; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PLASMIDS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; SIMPLEXVIRUS; THYMIDINE KINASE; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034213449     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Folkman, J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333: 1757-1763, 1995.
2. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
3. Dvorak, H. F., Brown, L. F., Detmer, M., and Dvrak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.
4. Berkman, R. A., Merrill, M. J., Reinhold, W. C., Monacci, W. T., Saxena, A., Clark, W. C., Robertson, J. T., Ali, I. U., and Oldfield, E. H. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Investig., 91: 153-159, 1993.
5. Plate, K. H., Breier, G., Weich, H. A., and Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (Lond.), 359: 845-848, 1992.
6. Brown, L. F., Berse, B., Jackman, R. W., Tonazzi, K., Manseau, E. J., Dvorak, H. F., and Senger, D. R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol., 143: 1255-1262, 1993.
7. Olson, T. A., Mohanraj, D., Carson, L. F., and Ramakrishnan, S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res., 54: 276-280, 1994.
8. Goldberg, M. A., and Schneider, T. J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem., 269: 4355-4359, 1994.
9. Ikeda, E., Achen, M. G., Breier, G., and Risau, W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem., 270: 19761-19766, 1995.
10. Forsythe, J. A., Jiang, B-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., and Semenza, G. L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol., 16: 4604-4613, 1996.
11. Levy, A. P., Levy, N. S., Wegner, S., and Goldberg, M. A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem., 270: 13333-13340, 1995.
12. Levy, N. S., Goldberg, M. A., and Levy, A. P. Sequencing of the human vascular endothelial growth factor (VEGF) 3′ untranslated region (UTR): conservation of five hypoxia-inducible RNA-protein binding sites. Biochim. Biophys. Acta, 1352: 167-173, 1997.
13. Damert, A., Machein, M., Breier, G., Fujita, M. Q., Hanahan, D., Risau, W., and Plate, K. H. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res., 57: 3860-3864, 1997.
14. Semenza, G. L., Roth, P. H., Fang, H. M., and Wang, G. L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem., 269: 23757-23763, 1994.
15. Firth, J. D., Ebert, B. L., Pugh, C. W., and Ratcliffe, P. J. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes; similarities with the erythropoietin 3′ enhancer. Proc. Natl. Acad. Sci. USA, 91: 6496-6500, 1994.
16. Chaplin, D. J., and Hill, S. A. Temporal heterogeneity in microregional crythrocyte flux in experimental solid tumours. Br. J. Cancer, 71: 1210-1213, 1995.
17. Teicher, B. A. Hypoxia and drug resistance. Cancer Metastasis Rev., 13: 139-168, 1994.
18. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 56: 4509-4515, 1996.
19. Pang, S., Taneja, S., Dardashti, K., Cohan, P., Kaboo, R., Sokoloff, M., Tso, C. L., Dekernion, J. B., and Belldegrun, A. S. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum. Gene Ther., 6: 1417-1426, 1995.
20. Osaki, T., Tanio, Y., Tachibana, I., Hosoe, S., Kumagai, T., Kawase, I., Oikawa, S., and Kishimoto, T. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res., 54: 5258-5261, 1994
21. Pages, J. C., Andreolelti, M., Bennoun, M., Vons, C., Elcheroth, J., Lehn, P., Houssin, D., Chapman, J., Briand, P., Benarous, R., Franco, D., and Weber, A. Efficient retroviral-mediated gene transfer into primary culture of murine and human hepatocytes; expression of the LDL receptor. Hum. Gene Ther., 6: 21-30, 1995.
22. Huber, B., Richards, C. A., and Krenitsky, T. A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA. 88: 8039-8043, 1991.
23. Vile, R. G., and Hart, I. R. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res., 53: 962-967, 1993.
24. Dachs, G. U., Patterson, A. V., Firth, J. D., Ratcliffe, P. J., Townsend, K. M. S., Stratford, I. J., and Harris, A. L. Targeting gene expression to hypoxic tumor cells. Nat. Med., 3: 515-520, 1997.
25. Takenaga, K., Nakamura, Y., Endo, H., and Sakiyama, S. Involvement of S100-related calcium-binding protein pEL98 (or mts1) in cell motility and tumor cell invasion. Jpn. J. Cancer Res., 85: 831-839, 1994.
26. Takenaga, K., Nakamura, Y., and Sakiyama, S. Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells. Oncogene, 14: 331-337, 1997.
27. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
28. Shima, D. T., Kuroki, M., Deutsch, U., Ng, Y-S., Adamis, A. P., and D'Amore, P. A. The mouse gene for vascular endothelial growth factor: genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J. Biol. Chem., 271: 3877-3883, 1996.
29. Takenaga, K. Characterization of low- and high-metastatic clones isolated from a Lewis lung carcinoma. Gann, 75: 61-71, 1984.
30. Takenaga, K., Tagawa, M., and Sakiyama, S. Therapeutic potency of transduction with herpes simplex virus thymidine kinase gene against multidrug resistant mouse leukemia cells. Anticancer Res., 16: 681-686, 1996.
31. Damert, A., Ikeda, E., and Risau, W. Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem. J., 327: 419-423, 1997.
32. Pope, I. M., Poston, G. J., and Kinsella, A. R. The role of the bystander effect in suicide gene therapy. Eur. J. Cancer, 33: 1005-1016, 1997.
33. Namba, H., Tagawa, M., Iwadate, Y., Kimura, M., Sueyoshi, K., and Sakiyama, S. Bystander effect-mediated therapy of experimental brain tumor by genetically engineered tumor cells. Hum. Gene Ther., 9: 5-11, 1998.
34. Yang, L., Chiang, Y., Lenz, H. J., Danenberg, K. D., Spears, C. P., Gordon, E. M., Anderson, W. F., and Parekh, D. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum. Gene Ther., 20: 719-728, 1998.
35. Holmgren, L., O'Reilly, M. S., and Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1: 149-153, 1995.
36. Balbay, M. D., Pettaway, C. A., Kuniyasu, H., Inoue, K., Ramirez, E., Li, E., Fidler, I. J., and Dinney, C. P. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin. Cancer Res., 5: 783-789, 1999.
37. Connolly, J. M., and Rose, D. P. Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice. J. Urol., 160: 932-936, 1998.
38. Takahashi, Y., Tucker, S. L., Kitadai, Y., Koura, A. N., Bucana, C. D., Cleary, K. R., and Ellis, L. M. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch. Surg., 112: 541-546, 1997.
39. Shibata, T., Akiyama, N., Noda, M., Sasaki, K., and Hiraoka, M. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int. J. Radiat. Oncol. Biol. Phys., 42: 913-916, 1998.